| Quarterly Financials | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 232 | 100 | 129 | 116 | 162 | 147 | 171 |
| Expenses | 217 | 97 | 117 | 108 | 147 | 134 | 160 |
| EBITDA | 15 | 3 | 12 | 9 | 15 | 12 | 11 |
| Operating Profit % | 6 % | 2 % | 9 % | 7 % | 9 % | 8 % | 5 % |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 6 | 4 | 4 | 4 | 4 | 6 | 6 |
| Profit Before Tax | 9 | -2 | 8 | 4 | 10 | 5 | 4 |
| Tax | 2 | -0 | 2 | 1 | 3 | 1 | 0 |
| Net Profit | 7 | -1 | 6 | 3 | 7 | 4 | 4 |
| EPS in ₹ | 0.27 | -0.05 | 0.24 | 0.12 | 0.31 | 0.16 | 0.16 |
Sudarshan Pharma Industries
Sudarshan Pharma Industries
25.32
-1.33
(-4.99%)
Q3 Quarterly Results are out. Check out the updated financials3 days ago
Show All
Key Fundamentals
Market Cap
641.40 Cr
EPS
0.66
PE Ratio
35.53
Dividend Yield
0.00 %
Industry
Chemicals 52 Week High
53.50
52 Week Low
24.69
PB Ratio
4.58
Debt to Equity
1.13
Sector
Dyes & Pigments Actual
Company News
View All News
Sudarshan Pharma Industries Reports Mixed Q2 Results with Revenue Growth but Profit Decline3 days ago
Sudarshan Pharma Industries reported Q2 consolidated net profit of 42 million rupees, down from 59 million rupees in the same period last year. The company's revenue increased to 1.69 billion rupees compared to 1.28 billion rupees year-over-year. EBITDA declined to 92 million rupees from 130 million rupees, while EBITDA margin compressed to 5.5% from 10.1% in the previous year.
Umesh Luthra has submitted his resignation as Independent Director of Sudarshan Pharma Industries Limited, effective October 18, 2025. The resignation is attributed to pre-occupation, with no other material reasons cited. Luthra, who holds DIN 06692755, has requested the company to complete necessary formalities with stock exchanges, Ministry of Corporate Affairs, and other relevant authorities.
Sudarshan Pharma Industries Limited submitted unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. The company received Rs. 2,01,27,549.29 from a Dubai Court award against Regans International DMCC and Nand Biharilal Chhabaria, with balance amount pending. The company acquired 100% stake in Cibachem General Trading LLC, Dubai for Rs. 55 lakhs on August 5, 2025. Sudarshan Pharma entered a definitive agreement to acquire operational manufacturing facility in Telangana from Srigen Lifesciences for Rs. 25.5 crores. The Board approved raising funds up to Rs. 1,500 crores through various securities, with BSE granting in-principle approval for FCCB issuance up to USD 35 million on September 16, 2025. The company adopted Indian Accounting Standards voluntarily with transition date of April 1, 2024.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,216.60 | #1 9,679.90 | 112.79 | #1 3,379.00 | #1 32.20 | 60 | 87.07 | 28.16 | |
567.75 | 3,506.20 | 19.17 | 854.90 | 14.72 | #1 265 | -89.05 | 53.86 | |
568.00 | 1,531.10 | 292.02 | 178.80 | 8.23 | 3 | 150.00 | 62.27 | |
519.05 | 1,381.70 | 18.94 | 843.80 | 5.55 | 51 | 228.85 | 28.15 | |
423.85 | 1,324.20 | 19.84 | 817.10 | 10.88 | 59 | 64.06 | 51.01 | |
483.00 | 1,323.20 | #1 16.81 | 707.10 | 23.84 | 75 | 22.42 | 43.87 | |
228.60 | 849.60 | 17.40 | 601.60 | 17.68 | 39 | 79.69 | 62.52 | |
60.73 | 766.70 | 26.23 | 1,756.70 | 23.76 | 19 | #1 891.67 | 40.29 | |
25.32 | #9 641.40 | #7 35.53 | #8 507.60 | #7 8.90 | #8 16 | #9 -33.90 | 41.14 | |
194.70 | 350.50 | 76.83 | 163.10 | 8.01 | 4 | 18.18 | 49.67 |
Growth Rate
Revenue Growth
8.90 %
Net Income Growth
39.13 %
Cash Flow Change
354.45 %
ROE
18.34 %
ROCE
32.98 %
EBITDA Margin (Avg.)
53.39 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 99 | 138 | 233 | 283 | 402 |
| Fixed Assets | 6 | 7 | 20 | 26 | 24 |
| Current Assets | 88 | 130 | 199 | 237 | 335 |
| Capital Work in Progress | 0 | 1 | 0 | 2 | 6 |
| Investments | 0 | 0 | 0 | 2 | 2 |
| Other Assets | 93 | 131 | 213 | 254 | 371 |
| Total Liabilities | 99 | 138 | 233 | 283 | 402 |
| Current Liabilities | 71 | 103 | 119 | 161 | 260 |
| Non Current Liabilities | 6 | 5 | 13 | 11 | 11 |
| Total Equity | 23 | 30 | 101 | 112 | 132 |
| Reserve & Surplus | 13 | 20 | 77 | 88 | 104 |
| Share Capital | 10 | 10 | 24 | 24 | 24 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -2 | 0 | -1 | 12 | -12 | 0 |
| Investing Activities | -3 | -1 | -2 | -26 | -7 | -20 |
| Operating Activities | 1 | 3 | -4 | -29 | 8 | 35 |
| Financing Activities | -0 | -2 | 4 | 66 | -12 | -14 |
Share Holding
| % Holding | Mar 2023 | Sept 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Jun 2025 |
| Promoter | 57.39 % | 57.39 % | 57.39 % | 57.39 % | 57.39 % | 57.39 % |
| FIIs | 0.00 % | 1.40 % | 1.40 % | 13.07 % | 18.45 % | 19.48 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.05 % |
| Public / Retail | 20.35 % | 27.04 % | 23.61 % | 23.20 % | 18.18 % | 17.14 % |
| Others | 22.26 % | 14.16 % | 17.59 % | 6.33 % | 5.98 % | 5.94 % |
| No of Share Holders | 2,785 | 983 | 913 | 787 | 1,212 | 1,327 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.3 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.05 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 26 Aug 2023 |  Dividend | ₹ 0.30 /share | 25 Aug 2023 | 6.75 | 8.15 |
| 05 Feb 2024 |  Extraordinary General Meeting | NA | 05 Feb 2024 | 7.53 | 7.71 |
| 30 Sept 2024 | Extraordinary General Meeting | NA | 30 Sept 2024 | 21.52 | 41.86 |
| 30 Sept 2024 |  Annual General Meeting | NA | 30 Sept 2024 | 41.89 | 41.86 |
| 31 Oct 2024 |  Quarterly Result Announcement | NA | 31 Oct 2024 | 35.30 | 38.48 |
| 30 Sept 2024 |  Split | 1:10 | 23 Nov 2024 | 41.86 | 41.86 |
| 04 Feb 2025 | Extraordinary General Meeting | NA | 04 Feb 2025 | 49.79 | 40.30 |
| 24 Apr 2025 | Quarterly Result Announcement | NA | 24 Apr 2025 | 29.53 | 27.81 |
| 12 Jun 2025 | Extraordinary General Meeting | NA | 12 Jun 2025 | 29.98 | 31.22 |
| 25 Jul 2025 | Annual General Meeting | NA | 25 Jul 2025 | 29.22 | 26.65 |
| 11 Aug 2025 | Extraordinary General Meeting | NA | 11 Aug 2025 | 29.20 | 30.00 |
| 14 Aug 2025 | Quarterly Result Announcement | NA | 14 Aug 2025 | 30.00 | 30.00 |
| 18 Oct 2025 | Quarterly Result Announcement | NA | 18 Oct 2025 | 27.55 | 26.90 |
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Change in Directorate4 days ago
4 days agoFinancial Results For The Quarter And Half Year Ended 30-Sep-20255 days ago
5 days agoBoard Meeting Intimation for Approval Of Financial Results For The Quarter And Half Year Ended 30-Sep-20258 days ago
8 days agoClosure of Trading WindowSep 30, 2025
Sep 30, 2025Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 18, 2025
Aug 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 18, 2025
Aug 18, 2025Announcement under Regulation 30 (LODR)-AcquisitionAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 14, 2025
Aug 14, 2025Financial Results For The Quarter 30-06-2025Aug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportAug 12, 2025
Aug 12, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMAug 12, 2025
Aug 12, 2025Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Scheduled To Be Held On Thursday 14Th August 2025Aug 11, 2025
Aug 11, 2025Proceedings Of Extraordinary General Meeting Held On Monday 11Th August 2025Aug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Aug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 05, 2025
Aug 05, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 25, 2025
Jul 25, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 25, 2025
Jul 25, 2025Proceedings Of Annual General Meeting Held On 25Th July 2025Jul 25, 2025
Jul 25, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 21, 2025
Jul 21, 2025Notice Of Extraordinary General Meeting Of The CompanyJul 17, 2025
Jul 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Jul 02, 2025Annual General Meeting On Friday 25Th July 2025 At 3.00 P.M. ISTJul 01, 2025
Jul 01, 2025Reg. 34 (1) Annual Report.Jul 01, 2025
Jul 01, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesJun 19, 2025
Jun 19, 2025Board Meeting Intimation for Meeting Of The Board Of Directors To Be Held On Thursday 19-June-2025Jun 16, 2025
Jun 16, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 14, 2025
Jun 14, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMJun 13, 2025
Jun 13, 2025Proceedings Of Extraordinary General Meeting Held On 12Th June 2025Jun 12, 2025
Jun 12, 2025Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jun 04, 2025
Jun 04, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 17, 2025
May 17, 2025Extraordinary General Meeting On 12/June/2025May 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 02, 2025
May 02, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 02, 2025
May 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 26, 2025
Apr 26, 2025Financial Results For The Financial Year Ended March 31 2025Apr 24, 2025
Apr 24, 2025Board Meeting Intimation for Approval Of Financial Results On Thursday 24-04-2025Apr 21, 2025
Apr 21, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 21, 2025
Apr 21, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 03, 2025
Apr 03, 2025Technical Indicators
RSI(14)
Neutral 41.14
ATR(14)
Less Volatile 1.18
STOCH(9,6)
Neutral 31.24
STOCH RSI(14)
Neutral 56.11
MACD(12,26)
Bullish 0.02
ADX(14)
Strong Trend 27.60
UO(9)
Bearish 49.19
ROC(12)
Uptrend And Accelerating 2.58
WillR(14)
Neutral -67.26
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
